Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Quanterix ( (QTRX) ) is now available.
On July 8, 2025, Quanterix Corporation completed its acquisition of Akoya Biosciences, creating a comprehensive platform for measuring biomarkers across blood and tissue. This acquisition is expected to expand Quanterix’s market from $1 billion to $5 billion and accelerate its path to profitability by 2026. As part of the merger, Akoya designated Scott Mendel and Myla Lai-Goldman, MD, to join Quanterix’s Board of Directors, replacing Martin D. Madaus, PhD, and Sarah Hlavinka, who resigned on July 7, 2025. The merger positions Quanterix as a scaled leader in early disease detection for neurology, oncology, and immunology markets.
The most recent analyst rating on (QTRX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.
Spark’s Take on QTRX Stock
According to Spark, TipRanks’ AI Analyst, QTRX is a Neutral.
Quanterix’s overall stock score is driven primarily by its growth potential and strategic initiatives, such as product launches and merger synergies. However, significant risks remain due to ongoing financial losses and valuation challenges. Positive technical momentum and corporate events provide some support, but profitability and cash flow improvements are crucial for future performance.
To see Spark’s full report on QTRX stock, click here.
More about Quanterix
Quanterix Corporation is a leader in the field of ultra-sensitive biomarker detection, utilizing its Simoa® technology to support research in neurology, oncology, immunology, cardiology, and infectious disease. The company is known for its precision instruments and digital immunoassay technology, which have been instrumental in advancing disease understanding and management. Quanterix has been a trusted partner in the scientific community for nearly two decades, with its research published in over 3,400 peer-reviewed journals.
Average Trading Volume: 770,736
Technical Sentiment Signal: Sell
Current Market Cap: $244.8M
For an in-depth examination of QTRX stock, go to TipRanks’ Overview page.